Aspen Pharmacare’s normalised headline earnings have risen by 28% in constant currency, driven by an unprecedented surge in demand for the weight-loss medication Mounjaro in South Africa.
The growth in profitability comes despite the company reporting flat overall revenue, indicating a significant shift toward higher-margin specialised medicines within its product portfolio.
According to the company’s latest financial disclosures, Mounjaro has rapidly captured 53% of the South African weight-loss market, establishing a dominant position in a high-growth therapeutic segment.
Stephen Saad, the billionaire founder of Aspen Pharmacare, noted that the speed of adoption for these weight-loss drugs is faster than any other product launch he has witnessed during his career.
Mounjaro, developed by the US-based pharmaceutical giant Eli Lilly, belongs to a class of GLP-1 receptor agonists that have transformed the global treatment of obesity and type 2 diabetes.
The drug’s success in the South African market reflects a broader global trend where appetite-suppressing medications are seeing massive commercial uptake, often outpacing the manufacturing capacity of their producers.
Aspen’s ability to leverage this demand has allowed the group to maintain strong earnings growth even as other areas of its business faced revenue stagnation.
Aspen’s Strategic Shift Toward High-Value Biologics
The performance of Mounjaro is part of a wider strategic pivot by Aspen to move away from low-margin generic pharmaceuticals toward specialised medicines and biologics.
For years, the company operated primarily as a provider of affordable generic drugs for emerging markets. However, the transition into high-value biologics—complex medicines derived from living organisms—has provided a new engine for profit growth.
The weight-loss segment is particularly lucrative because it targets a chronic condition with a massive patient base, ensuring long-term recurring revenue streams.
Industry analysts note that the dominance of GLP-1 drugs is not limited to South Africa. Globally, the market is currently a duopoly between Eli Lilly and Novo Nordisk, with the latter producing the widely known drug Ozempic.
Aspen’s ability to secure and distribute these products effectively in the Southern African region has given it a competitive edge over smaller distributors and local pharmacies.
This shift also reduces the company’s vulnerability to the pricing pressures typically associated with the generic drug market, where government procurement tenders often drive prices down to razor-thin margins.
Beyond weight loss, Aspen has been expanding its footprint in anaesthetics and other critical care medicines, further diversifying its revenue base away from commodity-style pharmaceuticals.
The company’s financial resilience is also supported by its global manufacturing capabilities, which allow it to pivot production based on market demand and regulatory approvals.
However, the reliance on high-cost specialised drugs may invite increased scrutiny from healthcare regulators and insurance providers regarding drug pricing and accessibility in the African market.
The company’s next primary challenge will be managing supply chain constraints. Global shortages of GLP-1 drugs have been frequent, and maintaining a consistent supply of Mounjaro will be critical to retaining its 53% market share.
Aspen is expected to continue monitoring the clinical expansion of these drugs, as new research suggests they may also be effective in treating sleep apnea and cardiovascular diseases, potentially expanding the addressable market even further.
Explore more Business stories and analysis from Business Elites Africa.
